NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/26/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization6.54 mln
Float3.15 mln
Earnings Date08/12/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-8.15
Highly reliable
Relative Strength
89
/ 100
Strongly outperforming
Debt / Equity
0.80
Moderate leverage
ROE
-536
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
GeoVax Labs is a US-based biotech company focused on developing vaccines and treatments for serious infectious diseases and cancer. Its pipeline spans conditions ranging from COVID-19, HIV, and Ebola to solid tumor cancers, with several candidates already in clinical trials and others in earlier stages of research. The company works alongside prominent partners including the National Institutes of Health and the US Department of Defense. Founded in 1988 and based in Smyrna, Georgia, GeoVax applies its own proprietary technology platforms across all of its programs.
